|
GORAB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.7539000003205E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.01040000002983E-06 |
| Normal-vs-Stage2 |
4.64010000422732E-08 |
| Normal-vs-Stage3 |
4.49219999998363E-06 |
| Normal-vs-Stage4 |
2.29780000027269E-07 |
| Stage1-vs-Stage2 |
4.908200E-02 |
| Stage1-vs-Stage3 |
5.289000E-01 |
| Stage1-vs-Stage4 |
1.242950E-01 |
| Stage2-vs-Stage3 |
1.391950E-01 |
| Stage2-vs-Stage4 |
6.572600E-01 |
| Stage3-vs-Stage4 |
2.989600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.86440000005117E-06 |
| Normal-vs-AfricanAmerican |
1.441660E-02 |
| Normal-vs-Asian |
2.751000E-04 |
| Caucasian-vs-AfricanAmerican |
4.059200E-01 |
| Caucasian-vs-Asian |
6.854200E-01 |
| AfricanAmerican-vs-Asian |
6.026400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.50439999999386E-06 |
| Normal-vs-Female |
8.45719999587047E-08 |
| Male-vs-Female |
7.019800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.31140000003693E-06 |
| Normal-vs-Age(41-60Yrs) |
1.03149999997054E-06 |
| Normal-vs-Age(61-80Yrs) |
9.03809999952543E-07 |
| Normal-vs-Age(81-100Yrs) |
3.717900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.264800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.534800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.910000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.146600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.602200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.459200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.582400E-02 |
| Classical-VS-Follicular |
1.318710E-03 |
| Classical-VS-Other |
6.949000E-01 |
| Classical-VS-Normal |
2.26629999999783E-05 |
| Tall-VS-Follicular |
9.462200E-01 |
| Tall-VS-Other |
4.778800E-01 |
| Tall-VS-Normal |
1.14839999998395E-06 |
| Follicular-VS-Other |
4.709400E-01 |
| Follicular-VS-Normal |
5.9971000054837E-08 |
| Other-VS-Normal |
8.793600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.14629999994997E-07 |
| Normal-vs-N1 |
4.34820000000391E-05 |
| N0-vs-N1 |
9.688000E-01 |
|
|
